BioCentury | Aug 17, 2017
Finance

Built to purpose

...AB Bristol-Myers Squibb Co. (NYSE:BMY) Novo Seeds Pulmonary Single target 2014 2017 Phase Ib/IIa complete F-star Alpha Ltd....
BioCentury | May 4, 2017
Company News

BMS declines option for F-star's FS102

...Ltd. (Cambridge, U.K.) said Bristol-Myers Squibb Co. (NYSE:BMY) will not exercise an option to acquire F-star Alpha Ltd....
...across its oncology portfolio.” In 2014, F-star Biotechnology granted BMS an exclusive option to acquire F-Star Alpha...
...begin a Phase IIb trial. BMS was funding the compound's development. F-star Biotechnology spun out F-star Alpha...
BioCentury | Apr 28, 2017
Company News

BMS declines option for F-star's FS102

...Ltd. (Cambridge, U.K.) said Bristol-Myers Squibb Co. (NYSE:BMY) will not exercise an option to acquire F-star Alpha Ltd....
...breast and gastric cancer. In 2014, F-star Biotechnology granted BMS an exclusive option to acquire F-Star Alpha...
...of opportunities across its oncology portfolio” (see BioCentury, Nov. 3, 2014) . Jaime De Leon FS102 Bristol-Myers Squibb Co. F-star Alpha Ltd. F-star...
BioCentury | Oct 12, 2015
Clinical News

F-star Alpha, Bristol-Myers preclinical data

...rights to the Fc antibody fragment targeting HER2 from F-star Alpha (see BioCentury, Nov. 3, 2014). F-star Alpha Ltd....
BioCentury | Mar 23, 2015
Finance

Alize's assets

...Bristol-Myers Squibb Co. (NYSE:BMY) paid $50 million for an exclusive option to acquire the biotech's F-star Alpha Ltd....
...unit, which had a preclinical antibody fragment that is now in Phase I for cancer. F-star Alpha...
BioCentury | Nov 10, 2014
Company News

F-star, F-star Beta deal

...Beta's license spans 22 undisclosed oncology and immuno-oncology targets that F-star had previously licensed to F-star Alpha...
...antibodies. F-star Beta is the second asset-centric company F-star Biotechnology has created. It spun out F-star Alpha Ltd....
...Bristol-Myers Squibb Co. (NYSE:BMY, New York, N.Y.) agreed to pay up to $475 million to F-star Alpha...
BioCentury | Nov 5, 2014
Company News

After BMS deal, F-star launches second newco

...undisclosed. F-star Beta is the second asset-centric company F-star Biotechnology has created. It spun out F-star Alpha Ltd....
...week with Bristol-Myers Squibb Co. (NYSE:BMY). BMS agreed to pay up to $475 million to F-star Alpha...
...period (see BioCentury, Nov. 3) . Haurum said F-star Beta's shareholders are the same as F-star Alpha's...
BioCentury | Nov 3, 2014
Company News

F-star Alpha, Bristol-Myers deal

...Bristol-Myers Squibb received an exclusive option to acquire F-star Alpha and gain worldwide rights to FS102...
...F-star GmbH (Vienna, Austria) spun out F-star Alpha last year to house FS102. BMS will pay F-star Alpha...
...IIb testing and three-and-a-half years after starting Phase I testing. If BMS exercises the option, F-star Alpha's...
BioCentury | Nov 3, 2014
Finance

Shooting F-stars

...convenience and seller financial flexibility. F-star Biotechnology Ltd., a subsidiary of F-star GmbH , launched F-star Alpha...
BioCentury | Oct 29, 2014
Company News

BMS takes option to acquire F-star Alpha

...Bristol-Myers Squibb Co. (NYSE:BMY) obtained an exclusive option to acquire F-star Alpha Ltd. (Cambridge, U.K.). The Cambridge-based F-star...
...Cambridge, U.K.). The Cambridge-based F-star Biotechnology Ltd subsidiary of F-star GmbH (Vienna, Austria) spun out F-star Alpha...
...growth factor receptor 2 ( EGFR2 ; HER2 ; ErbB2 ; neu). BMS will pay F-star Alpha...
Items per page:
1 - 10 of 14
BioCentury | Aug 17, 2017
Finance

Built to purpose

...AB Bristol-Myers Squibb Co. (NYSE:BMY) Novo Seeds Pulmonary Single target 2014 2017 Phase Ib/IIa complete F-star Alpha Ltd....
BioCentury | May 4, 2017
Company News

BMS declines option for F-star's FS102

...Ltd. (Cambridge, U.K.) said Bristol-Myers Squibb Co. (NYSE:BMY) will not exercise an option to acquire F-star Alpha Ltd....
...across its oncology portfolio.” In 2014, F-star Biotechnology granted BMS an exclusive option to acquire F-Star Alpha...
...begin a Phase IIb trial. BMS was funding the compound's development. F-star Biotechnology spun out F-star Alpha...
BioCentury | Apr 28, 2017
Company News

BMS declines option for F-star's FS102

...Ltd. (Cambridge, U.K.) said Bristol-Myers Squibb Co. (NYSE:BMY) will not exercise an option to acquire F-star Alpha Ltd....
...breast and gastric cancer. In 2014, F-star Biotechnology granted BMS an exclusive option to acquire F-Star Alpha...
...of opportunities across its oncology portfolio” (see BioCentury, Nov. 3, 2014) . Jaime De Leon FS102 Bristol-Myers Squibb Co. F-star Alpha Ltd. F-star...
BioCentury | Oct 12, 2015
Clinical News

F-star Alpha, Bristol-Myers preclinical data

...rights to the Fc antibody fragment targeting HER2 from F-star Alpha (see BioCentury, Nov. 3, 2014). F-star Alpha Ltd....
BioCentury | Mar 23, 2015
Finance

Alize's assets

...Bristol-Myers Squibb Co. (NYSE:BMY) paid $50 million for an exclusive option to acquire the biotech's F-star Alpha Ltd....
...unit, which had a preclinical antibody fragment that is now in Phase I for cancer. F-star Alpha...
BioCentury | Nov 10, 2014
Company News

F-star, F-star Beta deal

...Beta's license spans 22 undisclosed oncology and immuno-oncology targets that F-star had previously licensed to F-star Alpha...
...antibodies. F-star Beta is the second asset-centric company F-star Biotechnology has created. It spun out F-star Alpha Ltd....
...Bristol-Myers Squibb Co. (NYSE:BMY, New York, N.Y.) agreed to pay up to $475 million to F-star Alpha...
BioCentury | Nov 5, 2014
Company News

After BMS deal, F-star launches second newco

...undisclosed. F-star Beta is the second asset-centric company F-star Biotechnology has created. It spun out F-star Alpha Ltd....
...week with Bristol-Myers Squibb Co. (NYSE:BMY). BMS agreed to pay up to $475 million to F-star Alpha...
...period (see BioCentury, Nov. 3) . Haurum said F-star Beta's shareholders are the same as F-star Alpha's...
BioCentury | Nov 3, 2014
Company News

F-star Alpha, Bristol-Myers deal

...Bristol-Myers Squibb received an exclusive option to acquire F-star Alpha and gain worldwide rights to FS102...
...F-star GmbH (Vienna, Austria) spun out F-star Alpha last year to house FS102. BMS will pay F-star Alpha...
...IIb testing and three-and-a-half years after starting Phase I testing. If BMS exercises the option, F-star Alpha's...
BioCentury | Nov 3, 2014
Finance

Shooting F-stars

...convenience and seller financial flexibility. F-star Biotechnology Ltd., a subsidiary of F-star GmbH , launched F-star Alpha...
BioCentury | Oct 29, 2014
Company News

BMS takes option to acquire F-star Alpha

...Bristol-Myers Squibb Co. (NYSE:BMY) obtained an exclusive option to acquire F-star Alpha Ltd. (Cambridge, U.K.). The Cambridge-based F-star...
...Cambridge, U.K.). The Cambridge-based F-star Biotechnology Ltd subsidiary of F-star GmbH (Vienna, Austria) spun out F-star Alpha...
...growth factor receptor 2 ( EGFR2 ; HER2 ; ErbB2 ; neu). BMS will pay F-star Alpha...
Items per page:
1 - 10 of 14